Kruse Ryan C, Rossmiller Kristina D, Fleagle Timothy R
Department of Orthopedics and Rehabilitation, University of Iowa Sports Medicine, Iowa City, Iowa, USA.
Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
PM R. 2025 Apr;17(4):463-468. doi: 10.1002/pmrj.13271. Epub 2024 Oct 9.
Osteoarthritis is a chronic degenerative disease affecting 500 million people throughout the world. Although orthobiologics have been proposed as a symptom and disease modifying treatment for osteoarthritis, there is significant heterogeneity in the results of the orthobiologic procedures in the literature. One possible explanation for the heterogeneity is the inconsistent reporting and description of the postorthobiologic protocols. The goal of this scoping review was to identify the current literature on the use of orthobiologics for osteoarthritis and critically evaluate the postorthobiologic protocol within these studies. A total of 200 identified studies met inclusion criteria. In 37.5% of studies, there was no mention of a postorthobiologic protocol. Of the 125 studies that did mention a postorthobiologic protocol, only 38.4% included a rehabilitation protocol, 21.6% included postprocedure weightbearing restrictions, and only 2 (1.6%) mentioned the use of durable medical equipment. Nonsteroidal anti-inflammatory drug restriction was described in 91.2% of study protocols, whereas corticosteroids and immunosuppressants were restricted in 84.8% and 19.2% of protocols, respectively. The results of this scoping review demonstrate the inconsistent reporting of postorthobiologic procedure protocols in the literature, with significant heterogeneity in those that are described. These findings highlight the need for future research and improved reporting of postorthobiologic protocols.
骨关节炎是一种慢性退行性疾病,全球有5亿人受其影响。尽管再生生物制品已被提议作为骨关节炎的症状缓解和疾病改善治疗方法,但文献中再生生物制品治疗程序的结果存在显著异质性。异质性的一个可能解释是再生生物制品治疗后方案的报告和描述不一致。本综述的目的是识别目前关于使用再生生物制品治疗骨关节炎的文献,并严格评估这些研究中的再生生物制品治疗后方案。总共200项已识别的研究符合纳入标准。在37.5%的研究中,未提及再生生物制品治疗后方案。在125项提及再生生物制品治疗后方案的研究中,只有38.4%包括康复方案,21.6%包括治疗后负重限制,只有2项(1.6%)提及使用耐用医疗设备。91.2%的研究方案描述了非甾体抗炎药的限制,而分别有84.8%和19.2%的方案限制了皮质类固醇和免疫抑制剂的使用。本综述的结果表明,文献中再生生物制品治疗后程序方案的报告不一致,所描述的方案存在显著异质性。这些发现凸显了未来研究以及改进再生生物制品治疗后方案报告的必要性。